Incretins are gut hormones that play a vital role in blood glucose regulation and digestive control. Glucagon-like peptide-1 (GLP-1), the principal incretin affecting gastric motility, inhibits gastric emptying by slowing the rate at which stomach contents move into the small intestine. This mechanism occurs predominantly through vagal and central nervous system pathways, helping to moderate postprandial glucose peaks and enhance satiety. Understanding how incretins inhibit gastric emptying is essential for healthcare professionals prescribing GLP-1 receptor agonist therapies for type 2 diabetes and obesity, as this effect underlies both therapeutic benefits and common gastrointestinal side effects. This article explores the mechanisms, clinical implications, and management strategies associated with incretin-mediated gastric emptying delay.

How Incretins Affect Gastric Emptying

Incretins are gastrointestinal hormones released in response to nutrient intake, playing a crucial role in glucose homeostasis and digestive regulation. The two principal incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Of these, GLP-1 is the primary mediator of gastric emptying inhibition—the slowing of the rate at which stomach contents move into the small intestine. GIP has minimal effect on gastric emptying in humans at physiological concentrations.

GLP-1 slows gastric emptying predominantly through vagal afferent pathways and central nervous system mechanisms. When food enters the gastrointestinal tract, GLP-1 is secreted from enteroendocrine L-cells in the distal ileum and colon. GLP-1 activates receptors on vagal afferent neurons and in brainstem nuclei, modulating parasympathetic outflow to the stomach. This results in reduced antral contractions and increased pyloric tone, thereby delaying gastric emptying. Enteric neural circuits also contribute to this effect. The role of direct GLP-1 receptor activation on gastric smooth muscle remains uncertain and is likely secondary to neural pathways.

The physiological purpose of delayed gastric emptying is multifaceted. By slowing the delivery of nutrients to the small intestine, GLP-1 helps regulate the rate of glucose absorption into the bloodstream, thereby moderating postprandial glycaemic peaks. This mechanism also contributes to satiety signalling, as prolonged gastric distension sends feedback to appetite centres in the brain. The effect is dose-dependent and typically more pronounced with pharmacological GLP-1 receptor agonist therapies than with endogenous GLP-1 secretion.

Delayed gastric emptying may affect the absorption and timing of some concomitant oral medicines, particularly with short-acting GLP-1 receptor agonists such as exenatide twice daily and lixisenatide. Patients should be advised to follow specific timing instructions in the Summary of Product Characteristics (SmPC) for individual agents.

Understanding this mechanism is essential for healthcare professionals prescribing GLP-1-based medications, as the gastric emptying effect underlies both therapeutic benefits and potential adverse effects associated with these agents.

The Role of GLP-1 in Slowing Stomach Emptying

Glucagon-like peptide-1 (GLP-1) is the incretin responsible for inhibiting gastric emptying, with this effect representing one of its key physiological actions. Secreted primarily by L-cells in the distal ileum and colon, GLP-1 exerts its gastric effects through activation of GLP-1 receptors located in the gastrointestinal tract and brainstem.

The mechanism by which GLP-1 slows gastric emptying involves predominantly vagal afferent and central neural pathways. GLP-1 acts on vagal afferent neurons and brainstem nuclei (including the area postrema and nucleus tractus solitarius), modulating parasympathetic outflow that controls gastric motility. This leads to reduced antral contractions and increased pyloric tone, thereby slowing the passage of gastric contents into the duodenum. Enteric neural circuits within the gastrointestinal wall also contribute to this coordinated inhibitory effect.

Naturally occurring GLP-1 has a very short half-life (approximately 2 minutes) due to rapid degradation by the enzyme dipeptidyl peptidase-4 (DPP-4). However, pharmaceutical development has produced GLP-1 receptor agonists with extended half-lives. These include:

• Short-acting agents: exenatide (twice daily) and lixisenatide (once daily)

• Longer-acting agents: liraglutide (once daily), dulaglutide (once weekly), and semaglutide (once weekly or once daily oral)

These agents maintain prolonged GLP-1 receptor activation, resulting in sustained effects on gastric emptying throughout the dosing interval.

Research has demonstrated that the magnitude of gastric emptying delay varies among different GLP-1 receptor agonists. Short-acting agents such as exenatide twice daily and lixisenatide produce more pronounced acute effects on gastric emptying compared to longer-acting weekly formulations such as dulaglutide and semaglutide. With longer-acting agents, some degree of tachyphylaxis (reduced response over time) to the gastric emptying effect may occur, though glucose-lowering efficacy is maintained through other mechanisms including enhanced insulin secretion and glucagon suppression. The clinical significance of these differences continues to be evaluated in ongoing studies.

Clinical Implications for Diabetes and Weight Management

The inhibition of gastric emptying by GLP-1 receptor agonist therapies contributes significantly to their therapeutic efficacy in type 2 diabetes mellitus and obesity management. By slowing the rate at which glucose enters the circulation after meals, these medications help reduce postprandial hyperglycaemia—a key target in diabetes management.

In diabetes care, the gastric emptying effect complements other GLP-1 actions, including glucose-dependent insulin secretion and glucagon suppression. This multi-pronged approach helps patients achieve better glycaemic control. NICE guideline NG28 (Type 2 diabetes in adults: management) recognises GLP-1 receptor agonists as valuable treatment options, particularly for adults with type 2 diabetes who have elevated body mass index or established cardiovascular disease. When GLP-1 receptor agonists are used in combination with insulin or a sulfonylurea, there is an increased risk of hypoglycaemia, and dose reduction of the insulin or sulfonylurea should be considered to minimise this risk.

For weight management, delayed gastric emptying plays a crucial role in appetite regulation and caloric reduction. Prolonged gastric distension enhances satiety signals, helping patients feel fuller for longer periods after eating. This effect, combined with central appetite suppression, contributes to the significant weight loss observed in clinical trials of GLP-1 receptor agonists. NICE technology appraisal TA875 recommends semaglutide 2.4 mg (Wegovy) for managing overweight and obesity in adults, within specific criteria: initial body mass index ≥35 kg/m² (or ≥32.5 kg/m² in people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds) with at least one weight-related comorbidity, and as part of a specialist weight management service. Treatment should be stopped if less than 5% body weight is lost after 6 months at the maintenance dose. Similar criteria apply to liraglutide 3 mg (Saxenda) under NICE TA664.

Healthcare professionals should exercise caution when prescribing GLP-1 receptor agonists to patients with pre-existing severe gastrointestinal disease, including gastroparesis, as these conditions may be exacerbated. Perioperative considerations are also important: patients taking GLP-1 receptor agonists should inform their surgical and anaesthetic team, as delayed gastric emptying increases the risk of pulmonary aspiration during anaesthesia. UK perioperative guidance should be followed regarding timing of the last dose before elective procedures.

The therapeutic benefits must be balanced against potential tolerability issues, and patient education regarding realistic expectations and side effect management is essential for treatment adherence and success.

Side Effects Related to Delayed Gastric Emptying

The inhibition of gastric emptying by GLP-1 receptor agonist therapies, whilst therapeutically beneficial, commonly produces gastrointestinal adverse effects that represent the most frequent reason for treatment discontinuation. Understanding these side effects enables healthcare professionals to counsel patients appropriately and implement management strategies.

Nausea is the most commonly reported adverse effect, with incidence varying by agent, dose, and indication. In clinical trials, nausea has been reported in a substantial proportion of patients initiating GLP-1 receptor agonist therapy, particularly during dose escalation. This symptom typically results from delayed gastric emptying causing prolonged gastric distension and altered gastric accommodation. Nausea is usually most pronounced during treatment initiation and dose escalation, often improving over several weeks as physiological adaptation occurs.

Vomiting, dyspepsia, and abdominal discomfort are also frequently reported, stemming from the same underlying mechanism. Some patients describe early satiety or feeling uncomfortably full after consuming normal meal portions. These symptoms can impact nutritional intake and quality of life, particularly if not adequately managed.

More serious gastrointestinal concerns require prompt recognition and action:

• Pancreatitis: Severe, persistent abdominal pain (often radiating to the back) may indicate acute pancreatitis. The GLP-1 receptor agonist should be stopped immediately, and the patient should seek urgent medical assessment. Serum lipase or amylase should be measured if pancreatitis is suspected.

• Gallbladder disease: Right upper quadrant pain, fever, or jaundice may indicate cholecystitis or cholelithiasis. Patients should be assessed promptly, and imaging may be required.

• Dehydration and acute kidney injury: Persistent vomiting or diarrhoea can lead to dehydration and acute kidney injury, particularly in patients with pre-existing renal impairment. Patients should be advised to maintain adequate fluid intake and seek medical advice if they develop signs of dehydration (reduced urine output, dizziness, dry mouth).

• Diabetic retinopathy: Rapid improvement in glycaemic control has been associated with temporary worsening of diabetic retinopathy. Patients with a history of retinopathy should be monitored appropriately.

Patients should be advised to contact their GP, diabetes specialist nurse, or NHS 111 if they experience persistent vomiting, severe abdominal pain, or inability to tolerate oral intake. In cases of severe or rapidly worsening symptoms, patients should call 999 or attend the nearest emergency department. Healthcare professionals should maintain a low threshold for investigating alternative causes of gastrointestinal symptoms, particularly if they develop after the initial adaptation period or worsen over time.

Reporting adverse reactions: Patients and healthcare professionals are encouraged to report suspected adverse drug reactions via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app. This supports ongoing pharmacovigilance and medicine safety monitoring.

Managing Gastrointestinal Symptoms on GLP-1 Receptor Agonist Therapies

Effective management of gastrointestinal symptoms related to delayed gastric emptying can significantly improve treatment adherence and patient outcomes. A structured approach combining dose titration, dietary modification, and symptomatic management forms the cornerstone of clinical practice.

Gradual dose escalation represents the most important strategy for minimising gastrointestinal side effects. Most GLP-1 receptor agonists are initiated at sub-therapeutic doses, with stepwise increases over several weeks to months according to the licensed dosing schedule. This approach allows physiological adaptation to occur and reduces the intensity of nausea and other symptoms. If symptoms are troublesome during up-titration, pausing the escalation or stepping back to the previous tolerated dose before re-attempting escalation after a few weeks may improve tolerability. Patients should be counselled that initial side effects are common but typically transient, with most individuals experiencing improvement within 4–8 weeks.

Dietary modifications can substantially alleviate symptoms. Patients should be advised to:

• Consume smaller, more frequent meals rather than large portions

• Eat slowly and chew food thoroughly

• Avoid high-fat foods, which further delay gastric emptying

• Stay well-hydrated but limit fluid intake during meals

• Identify and avoid personal trigger foods

• Consider eating the main meal earlier in the day when symptoms may be less pronounced

For persistent nausea, antiemetic medications may provide symptomatic relief, but must be used cautiously:

• Prochlorperazine may be considered for short-term use.

• Metoclopramide is restricted to short-term use (maximum 5 days) due to the risk of serious neurological adverse effects, including extrapyramidal disorders and tardive dyskinesia, as per MHRA guidance. It should be used at the lowest effective dose.

• Domperidone, if considered, is also restricted to short-term use at the lowest effective dose due to cardiac risks (QT prolongation and serious ventricular arrhythmia). It is contraindicated in patients with underlying cardiac conditions, significant electrolyte disturbances, or those taking other QT-prolonging medicines.

Patients should consult their GP or pharmacist before using antiemetics to ensure safe and appropriate use. Non-pharmacological alternatives such as ginger supplements or acupressure bands are sometimes tried by patients, though evidence for their efficacy in this context remains limited. Patients should discuss any supplements with a healthcare professional due to potential interactions and uncertain benefit.

Timing of concomitant oral medicines: Patients taking short-acting GLP-1 receptor agonists (exenatide twice daily or lixisenatide) should follow SmPC guidance on spacing oral medicines to minimise potential effects on absorption. For example, oral contraceptives and antibiotics should generally be taken at least one hour before the injection.

If symptoms prove intolerable despite these measures, healthcare professionals should consider switching to an alternative GLP-1 receptor agonist, as individual patient responses vary. Alternatively, switching to a DPP-4 inhibitor (which enhances endogenous incretin activity without sustained supraphysiological GLP-1 levels) typically produces fewer gastrointestinal side effects, though with more modest glycaemic and weight benefits. Regular follow-up and open communication regarding symptom burden ensures optimal therapeutic outcomes whilst maintaining patient safety and quality of life.

Reporting adverse reactions: Patients and healthcare professionals should report suspected adverse drug reactions via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Frequently Asked Questions